IBRX
ImmunityBio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.42
−8.28%Margins
Gross margin
94.6%
EBITDA margin
-538.5%
EBIT margin
-151.9%
Net margin
-598.6%
FCF margin
-174.0%
94.8%
Return on equity
-157.9%
Return on assets
107.8%
Return on invested capital
0.26x
Asset turnover
-$281.1M
Cash from operations
$0.34
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026